Skip to main content

ML-powered app and platform to identify skin changes over time

Project description

Artificial intelligence to assist in skin cancer screening

Malignant melanoma originates in the skin's melanocytes and is responsible for most deaths caused by skin cancer, due to the high risk of metastases. Early detection of melanoma has a 98 % survival rate, but late detection results only in a 10-25 % survival rate. People at high risk of developing skin cancer have to regularly monitor their skin and moles for changes as early detection is so critical for successful treatment. The EU has provided funding to Miiskin Aps for the development of a supporting tool to assist in the screening and monitoring of skin changes over time with an innovative AI-based application. The novel application will make the monitoring process more efficient and reliable, improving screening of mole changes through automatic photo comparison and unlocking possibilities for teledermatology.

Field of science

  • /medical and health sciences/clinical medicine/dermatology/melanoma
  • /natural sciences/computer and information sciences/artificial intelligence
  • /social sciences/sociology/demography/mortality
  • /medical and health sciences/clinical medicine/oncology/cancer
  • /medical and health sciences/clinical medicine/oncology/cancer/skin cancer

Call for proposal

H2020-SMEInst-2018-2020-1
See other projects for this call

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

MIISKIN APS
Address
Fruebjergvej 3
2100 København O
Denmark
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000